Skip to main content
Clinical Trials/ISRCTN99503308
ISRCTN99503308
Completed
Phase 3

Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch

niversity Medical Center Utrecht0 sites325 target enrollmentJanuary 2, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Acute ischaemic stroke and intracerebral haemorrhage
Sponsor
niversity Medical Center Utrecht
Enrollment
325
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31242931 protocol (added 28/06/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36058230/ (added 05/09/2022) 2019 Abstract results in https://doi.org/10.1177/2396987319848124 (added 13/02/2024) 2021 Abstract results in https://doi.org/10.1177/23969873211044666 (added 13/02/2024) 2022 Abstract results in https://doi.org/10.1177/23969873221087559 (added 13/02/2024)

Registry
who.int
Start Date
January 2, 2018
End Date
June 24, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 18 years or older
  • 2\. Probable diagnosis of acute stroke, as assessed by the paramedic in the prehospital setting
  • 3\. Score of 2 or 3 on the Face Arm Speech Test (FAST)
  • 4\. Systolic blood pressure \= 140 mm Hg
  • 5\. Possibility to start the trial treatment within 3 hours of symptom onset
  • 6\. Intention to transport the patient to one of the participating hospitals
  • 7\. Written informed consent (deferred)

Exclusion Criteria

  • 1\. Considerable pre\-stroke dependency in activities of daily living, defined as staying in a chronic nursing home or rehabilitation centre
  • 2\. Known pregnancy or lactation
  • 3\. Indication for acute treatment with nitroglycerin or known use of nitroglycerin in the previous 12 hours
  • 4\. Indication for acute reduction of blood pressure
  • 5\. Known hypersensitivity to GTN, nitrates in general, or the adhesives used in the patch
  • 6\. Glasgow Coma Scale \< 8
  • 7\. Known with any of the following heart disorders: myocardial insufficiency due to obstruction; aortic or mitral valve stenosis; constrictive pericarditis; hypertrophic obstructive cardiomyopathy; cardiac tamponade
  • 8\. Known marked anaemia, defined as haemoglobin \< 5 mmol/L
  • 9\. Known closed angle glaucoma
  • 10\. Known concomitant use of phosphodiesterase type\-5 inhibitors, (e.g. sildenafil, tadalafil, vardenafil)

Outcomes

Primary Outcomes

Not specified

Similar Trials